Hepatocyte-specific NEMO deletion promotes NK/NKT cell– and TRAIL-dependent liver damage

Naiara Beraza,1 Yann Malato,1 Leif E. Sander,1 Malika Al-Masaoudi,1 Julia Freimuth,1 Dieter Riethmacher,2 Gregory J. Gores,3 Tania Roskams,4 Christian Liedtke,1 and Christian Trautwein1

1Department of Internal Medicine III, University Hospital (RWTH) Aachen, Aachen 5205, Germany
2Human Genetics Division, Southampton University School of Medicine, Southampton SO16, England, UK
3Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic College of Medicine, Rochester, MN 55905
4Department of Pathology, Catholic University of Leuven, Leuven B-3000, Belgium

Nuclear factor κB (NF–κB) is one of the main transcription factors involved in regulating apoptosis, inflammation, chronic liver disease, and cancer progression. The IKK complex mediates NF–κB activation and deletion of its regulatory subunit NEMO in hepatocytes (NEMOΔhepa) triggers chronic inflammation and spontaneous hepatocellular carcinoma development. We show that NEMOΔhepa mice were resistant to Fas–mediated apoptosis but hypersensitive to tumor necrosis factor–related apoptosis–inducing ligand (TRAIL) as the result of a strong up–regulation of its receptor DR5 on hepatocytes. Additionally, natural killer (NK) cells, the main source of TRAIL, were activated in NEMOΔhepa livers. Interestingly, depletion of the NK1.1+ cells promoted a significant reduction of liver inflammation and an improvement of liver histology in NEMOΔhepa mice. Furthermore, hepatocyte-specific NEMO deletion strongly sensitized the liver to concanavalin A (ConA)–mediated injury. The critical role of the NK cell/TRAIL axis in NEMOΔhepa livers during ConA hepatitis was further confirmed by selective NK cell depletion and adoptive transfer of TRAIL–deficient1/2 mononuclear cells. Our results uncover an essential mechanism of NEMO–mediated protection of the liver by preventing NK cell tissue damage via TRAIL/DR5 signaling. As this mechanism is important in human liver diseases, NEMOΔhepa mice are an interesting tool to give insight into liver pathophysiology and to develop future therapeutic strategies.
Figure 1. Hepatocyte-specific NEMO-deleted mice (NEMO^{hepa}) are protected against Fas-mediated apoptosis. (A) Survival curve after i.p. injection of 0.5 µg/g Jo2, evidencing the resistance of NEMO^{hepa} mice to Fas-mediated death. (B–D) Macroscopic view of livers 3 h after Jo2 (B), liver weight/body weight ratio (B), serum transaminases (C), and H&E staining (D) showed fulminant hepatitis in NEMO^{f/f} mice after Jo2, whereas NEMO^{hepa}
system leads to massive apoptotic cell death and fulminant hepatitis (Ogasawara et al., 1993). More recently, liver steatosis has been shown to hypersensitize hepatocytes to Fas-mediated apoptosis, contributing to the progression of steatohepatitis and end-stage liver disease (Zou et al., 2007).

TRAIL, via its receptor DR5, selectively induces apoptosis of transformed and virally infected hepatocytes, and NF-κB-dependent signaling counteracts its detrimental effects (Luo et al., 2004). The cellular responses to TRAIL have been related to the inflammatory status of the liver, and DR5 up-regulation can be mediated by free fatty acids and bile acids, indicating a link between fat metabolism and TRAIL signaling (Higuchi et al., 2004; Malhi et al., 2007). This is supported by findings showing high levels of liver DR5 expression in nonalcoholic steatohepatitis patients (Malhi et al., 2007). Additionally, fatty liver disease activates the innate immune system by triggering NKT cells, promoting an unbalanced Th1/Th2 response in the liver (Guebre-Xabier et al., 2000). This contributes to create a proinflammatory environment where high IFN-γ expression is found. Furthermore, IFN-γ produced by activated NKT cells strongly induces NK cells to express TRAIL (Smyth et al., 2001).

Together, these data suggest that FasL and TRAIL could be involved in mediating the severe liver phenotype observed in NEMOΔhepa mice. In the present study, we aimed to characterize the implication of these cytokines and to uncover the pathophysiological mechanisms contributing to liver inflammation and further disease progression in NEMOΔhepa animals.

We demonstrate that NEMOΔhepa mice are resistant to Fas-mediated apoptosis, whereas they are hypersensitive to TRAIL-mediated cell death. Moreover, we highlight an essential role for NK cells, the main producers of TRAIL, in the spontaneous phenotype observed in NEMOΔhepa mice, as interfering with this cascade significantly improved liver homeostasis and attenuated the impact of T cell–mediated hepatitis in NEMOΔhepa mice.

RESULTS AND DISCUSSION

To better characterize the role of NEMO in hepatocytes, we generated NEMOloxP mice and crossed them with aliP-Cre transgenic animals to create NEMOΔi/Δi (WT) and NEMOΔhepa (KO) mice (Fig. S1, A and B). Hepatocyte-specific NEMO deletion led to a complete lack of NF-κB activation after TNF stimulation, confirming our previous results (Fig. S1 C; Luedde et al., 2007). Additionally, in consonance with our previous data (Luedde et al., 2007), NEMOΔhepa animals exhibited spontaneously elevated TNF and TNFR1 levels, although no significant differences were found in TNFR2 expression (Fig. S1 D). Immunohistochemistry (IHC) confirmed higher TNF expression in the nonparenchymal cell compartment in NEMOΔhepa mice (Fig. S1 D). Moreover, 12-wk-old NEMOΔhepa mice displayed high ALT levels (Fig. S1 E), accompanied by signs of nonalcoholic steatohepatitis, activation of progenitor cells, profuse inflammation, and features of chronic liver damage such as hepatocyte dysplasia and anisokaryosis (Fig. S1 F, top). The combination of these events contributed to HCC development in 1-yr-old NEMOΔhepa mice, as indicated by liver tumors and higher liver weight/body weight ratio (Fig. S1, F [bottom] and G).

Hepatocyte-specific NEMO deletion promotes hypersensitivity to exogenously administered TNF; however, the animals survived this challenge (Beraza et al., 2007). As NEMO deletion may also contribute to amplifying liver damage triggered by other TNF-related cytokines, we sought to investigate their implication in mediating the liver phenotype of NEMOΔhepa mice.

Fas activation promotes acute hepatic failure (Ogasawara et al., 1993). Hence, stimulation with an anti-Fas mAb (Jo2, 0.5 µg/g) resulted in the death of all NEMOΔi/Δi mice within 10 h (Fig. 1 A). Unexpectedly, NEMOΔhepa animals were less sensitive to Jo2, as 90% of the mice survived (Fig. 1 A). Macromscopic view confirmed that NEMOΔhepa livers remained unaffected while NEMOΔi/Δi showed significant blood accumulation and a higher liver weight/body weight ratio (Fig. 1 B). Accordingly, NEMOΔi/Δi mice showed clear signs of fulminant hepatitis, as high ALT levels, infiltrating PMN and RBC, necrosis, and apoptotic bodies were observed (Fig. 1, C and D). In contrast, we failed to detect any significant effects of Jo2 in NEMOΔhepa mice, as only the preexisting elevated ALT levels and parenchymal damage, caused by the spontaneous phenotype of these mice, was observed (Fig. 1, C and D). TUNEL assay, caspase 8, and caspase 3 activity confirmed resistance to Fas-induced apoptosis in NEMOΔhepa mice (Fig. 1, E and F).

These data may seem contradictory to reports showing that NF-κB inhibition sensitizes hepatocytes to Fas apoptosis (Hatano et al., 2000). However, as we previously described, NF-κB is one of the main factors responsible for activating Fas transcription (Kuhn et al., 2000). Thus, we hypothesized that NEMOΔhepa mice might have a defective turnover of this receptor, thereby promoting resistance to Jo2 apoptosis. In agreement with this, NEMOΔhepa mice exhibited reduced levels of Fas (25% less) and impaired up-regulation of Fas after Jo2 (Fig. 1 G). IHC confirmed these results, as Fas staining was almost negative on NEMOΔhepa mice after Jo2 (Fig. 1 G). Messenger RNA (mRNA) analysis on isolated primary hepatocytes corroborated the inability of NEMOΔhepa mice to express Fas (Fig. 1 H), which led to impaired NF-κB activation on these cells (not depicted).

remained unaffected. (E and F) TUNEL (E) and caspase 8 and 3 (F) activity analysis confirmed Jo2 apoptosis. Activity is represented in times versus untreated NEMOΔi/Δi (G and H) Fas mRNA and IHC analysis in whole liver (G) and isolated primary hepatocytes (H) showed stronger expression in WT compared with NEMOΔhepa mice. (I) TNF mRNA and cellular location indicated by IHC. (J) Western blotting showed phosphorylation of JNK1 (p45) and JNK2 (p54) in NEMOΔi/Δi mice after Jo2. JNK1 and GAPDH act as loading controls. Bars, 50 µm. Data are representative of three independent experiments. n = 4. * P < 0.05; ** P < 0.01; *** P < 0.001 (NEMOΔi/Δi vs. NEMOΔhepa). §§, P < 0.001; §§§, P < 0.001 (NEMOΔi/Δi vs. Jo2/NEMOΔi/Δi). Error bars represent SD.
Additionally, in accordance with the observation that Jo2/Fas induces TNF expression through NF-κB activation (Lu et al., 2002), we found a strong up-regulation of TNF in NEMO
f/f mice after Jo2 (43-fold), whereas it was barely regulated in NEMOΔαp50 mice (Fig. 1 I). IHC on liver sections confirmed macrophages as the main source of TNF after Fas activation, which likely explains the modest TNF regulation observed in NEMOΔαp50 mice (Fig. 1 I).

Finally, NEMO
f/f mice displayed strong c-Jun N-terminal kinase (JNK) phosphorylation, whereas it remained inactive in NEMOΔαp50 mice after Jo2 (Fig. 1 J), supporting the absence of cellular stress in our KO animals upon Fas activation. These results suggest that Fas is not an essential mediator of the pathogenesis observed in NEMOΔαp50 mice.

Thus, we next investigated the potential implication of TRAIL in the initiation and progression of chronic liver damage in our NEMO-deficient mice. As expected, low doses of TRAIL had no effect on NEMO
f/f mice, as ALT levels and liver architecture remained unaffected (Fig. 2, A and B). In clear contrast, TRAIL had a strong impact on NEMOΔαp50 mice, as a significant rise in serum ALT and massive liver damage, induced by profuse PMN infiltration, necrosis, and apoptosis, were observed (Fig. 2, A and B). TUNEL assay and caspase 3 activity confirmed the severity of TRAIL-mediated apoptosis on NEMOΔαp50 mice (Fig. 2, C and D). Previous work indicated that TRAIL induced JNK activation, leading to cellular apoptosis (Herr et al., 1999). Accordingly, we found that TRAIL promoted strong JNK activation in NEMOΔαp50 livers, whereas it remained inactive in NEMO
f/f mice (Fig. 2 E). Moreover, TRAIL administration promoted a significant induction of TNF in NEMOΔαp50 mice that was confirmed by IHC, uncovering the Kupffer cells as its main source (Fig. 2 F). These results suggest that hepatocyte–NEMO deletion promotes hypersensitivity to TRAIL-mediated apoptosis; hence, we next attempted to elucidate the potential mechanisms underlying this effect.

Interestingly, DR5 was highly expressed in livers of untreated NEMOΔαp50 mice, where it was mainly present in hepatocytes (Fig. 2 G). This was confirmed in vitro, where NEMOΔαp50 hepatocytes showed an eightfold increase in DR5 expression and a complete inability to activate NF-κB in response to TRAIL in contrast to WT cells (Fig. 2 S, A and B). Accordingly with our in vivo data, WT cells remained unaffected, whereas TRAIL induced JNK activation on hepatocytes lacking NEMO, leading to strong apoptotic cell death which was significantly abrogated by JNK inhibition with SP600125 (Fig. 2 S, C and D). The protection elicited by JNK inhibition, despite the absence of NF-κB in NEMO-deficient hepatocytes, suggests an essential role of DR5-JNK signaling during TRAIL-induced cellular damage in NEMOΔαp50 mice.

NK cells are the main producers of TRAIL in the liver (Smyth et al., 2001; Takeda et al., 2001). Earlier studies demonstrated that genetically or dietary-induced fatty liver disease promotes activation of these cells (Guebre-Xabier et al., 2000; Li et al., 2005). Thus, we hypothesized that similar alterations in the innate immune system might also arise in livers of NEMOΔαp50 mice.

NEMOΔαp50 livers had significantly reduced numbers of NK and NKT cells compared with NEMO
f/f littermates (Fig. 3 A). As NK cells’ activation is associated with their apoptosis, the lower NK1.1 + cell number found in NEMOΔαp50 livers could reflect their activation. Hence, NK1.1 + cells from NEMOΔαp50 mice exhibited significantly higher levels of annexin V when compared with NEMO
f/f mice (Fig. 3 B). Activation of NK cells involves strong production of proinflammatory cytokines, like IFN-γ and IL-12, promoting their cytotoxic activity and apoptosis (Vivier et al., 2008). Accordingly, we found higher IFN-γ and IL-12 (p35) expression associated with lower IL-4 levels in NEMOΔαp50 mice compared with WT littermates. Additionally, higher CCL5 (RANTES) levels found in NEMOΔαp50 livers (Fig. 3 C) may reflect a compensatory response to restore liver NK cells number (Morris and Ley, 2004). These data were confirmed on isolated NK1.1 + cells from livers of NEMOΔαp50 mice showing higher IFN-γ and CCL5 but lower IL4 levels (Fig. 3 D). FACS and mRNA analysis evidenced strong TRAIL expression on liver NK1.1 + cells from NEMOΔαp50 compared with WT mice (Fig. 3 E). These data suggest that hepatocyte–NEMO deletion correlates with an altered NK/NKT cell response. Moreover, the proactivity of TRAIL-producing NK cells to promote cytotoxicity against self-hepatocytes (Ochi et al., 2004) appears to be enhanced in NEMOΔαp50 mice, suggesting that this may represent a potential mechanism involved in the chronic inflammation and parenchymal damage observed in NEMOΔαp50 mice.

To test this hypothesis, we investigated the potential beneficial effects of NK/NKT cell inactivation in NEMOΔαp50 mice by using a NK1.1 mAb (PK–136). FACS and mRNA analysis confirmed efficient cell depletion after NK1.1 mAb administration (Fig. 3 F) that attenuated IFN-γ and CCL5 expression, correlating with strong amelioration of liver damage in NEMOΔαp50 mice (Fig. 3, H and I). FACS analysis confirmed the attenuation of the proinflammatory environment in NK1.1 mAb-treated NEMOΔαp50 mice, as a significant reduction of CD11b+ cells was detected (Fig. 3 J).

Based on our present data, which identify the critical detrimental role of NK1.1 + cells in the pathogenesis of liver injury in NEMOΔαp50 mice (Fig. 3), we further characterized the contribution of these cells during concanalavin A (ConA) hepatitis, where NKT cells activation have a major implication (Toyabe et al., 1997; Takeda et al., 2000).

Administration of 15 mg/kg ConA caused 100% mortality of NEMOΔαp50 mice within 16 h, whereas all NEMO
f/f mice survived (Fig. S3). To better define the molecular mechanism leading to the mortality of NEMOΔαp50 mice, we next administered 25 mg/kg ConA and sacrificed the animals 6 h after injection. ConA triggered a more severe hepatitis in NEMOΔαp50 mice compared to NEMO
f/f littermates. Massive destruction of liver parenchyma in NEMOΔαp50 mice were indicated by high ALT, strong inflammation, and necrotic and apoptotic cell death (Fig. 4, A–C). Moreover, ConA induced significantly higher levels of IFN-γ, IL-4, and CCL5 in NEMOΔαp50 compared with NEMO
f/f livers (Fig. 4 D). ELISA confirmed systemic IFN-γ elevation (Fig. 4 E).
Activated macrophages are the main producers of IL-12, which promotes NKT cell activation and further IFN-γ production (Trinchieri, 2003). This phenomenon may also occur in NEMOΔhepa mice, as IL12-p35 was significantly up-regulated before ConA and was further increased following injury (Fig. 4 D).

Expression of the antiinflammatory cytokine IL-10, which negatively regulates TNF, IFN-γ, and IL-12 after ConA (Louis et al., 1997), was significantly lower in NEMOΔhepa, indicating their inability to orchestrate a proper antiinflammatory response to ConA hepatitis (Fig. 4 D). As expected, up-regulation of TNF was observed in WT and NEMOΔhepa.
Figure 3. Hepatocyte-specific deletion of NEMO promotes spontaneous activation of liver NK/NKT cells, and administration of NK1.1-depleting mAb attenuates the damaging phenotype in NEMO<sup>hepa</sup> mice. (A) FACS analysis revealed a lower number of NK1.1<sup>+</sup>CD3<sup>−</sup> and NK1.1<sup>+</sup>CD3<sup>+</sup> cells in NEMO<sup>hepa</sup> mice. The graph represents the percentage of NK1.1<sup>+</sup> cells related to the percentage of CD45<sup>+</sup> cells in the liver. (B) FACS analysis of NK1.1<sup>+</sup>/annexin V<sup>+</sup> related to % of CD45<sup>+</sup> cells revealed strong apoptosis of NK1.1<sup>+</sup> cells in livers from NEMO<sup>hepa</sup> mice. (C) mRNA analysis of isolated NK1.1<sup>+</sup> cells confirmed cell activation and increased cytokine expression. (E) FACS analysis showed stronger TRAIL expression on NK1.1<sup>+</sup> cells from livers of NEMO<sup>hepa</sup> mice. mRNA analysis on isolated NK1.1<sup>+</sup> cells confirmed this. (F and G) FACS analysis proved effective depletion of NK1.1<sup>+</sup> cells (F) 40 h after NK1.1 mAb administration that reduced IFN-γ and CCL5 mRNA levels (G). (H–J) Serum ALT (H), H&E staining (I), and FACS analysis (J; CD11b<sup>+</sup> cells) were used as markers of liver damage and inflammation. Bars, 50 µm. All data are representative of three independent experiments. n = 4. *, P < 0.05; **, P < 0.01; ***, P < 0.001 (NEMO<sup>eff</sup> vs. NEMO<sup>hepa</sup>). §§, P < 0.01 (NEMO<sup>hepa</sup> vs. Nk1.1mAb/NEMO<sup>hepa</sup>). Error bars represent SD.
mice after ConA but no significant differences were observed between genotypes (Fig. 4, D and E).

NK/NK1T cell depletion lead to a remarkable improvement of liver parenchyma, indicated by lower ALT, necrosis, inflammation, and infiltration of PMNs (Fig. 5, A and B). Attenuation of ConA induced liver apoptosis after NK1.1 mAb treatment was confirmed by TUNEL assay and caspase 8 activity (Fig. 5 C). Accordingly, IFN-γ, CCL5, and IL-4 levels were lower after ConA in NK1.1-depleted NEMO<sup>Δhepa</sup> mice (Fig. 5 D), and systemic IFN-γ and TNF serum levels were significantly reduced (Fig. 5 E). Remnant cytokine expression despite NK1.1 mAb is likely explained by the fact that ConA promotes activation of other cell compartments like macrophages.

Figure 4. ConA promotes stronger liver damage in NEMO<sup>Δhepa</sup> mice than in NEMO<sup>f/f</sup> animals. (A–C) ALT serum levels (A), H&E staining and TUNEL analysis (B), and quantification of caspase 8 and 3 activity (C) measured 6 h after 25 mg/kg ConA showed strong liver damage in NEMO<sup>Δhepa</sup> mice. (D) mRNA levels of IFN-γ, IL-4, IL-12p35, TNF, and IL-10. All RT-PCR data are presented as times versus NEMO<sup>f/f</sup> untreated. (E) ELISA of IFN-γ and TNF in serum before and 6 h after 25 mg/kg ConA. Bars, 50 µm. All data are representative of three independent experiments. n = 4. *, P < 0.05; **, P < 0.01; ***, P < 0.001 (NEMO<sup>f/f</sup> vs. NEMO<sup>Δhepa</sup>). §§, P < 0.01; §§§, P < 0.001 (NEMO<sup>Δhepa</sup> vs. ConA/NEMO<sup>Δhepa</sup>). Error bars represent SD.
Figure 5. NK1.1 cell depletion and adoptive transfer of TRAIL^-/- MNCs protects NEMO\^hepa mice against ConA-mediated fulminant hepatitis. (A–C) ALT serum levels (A), H&E staining (B), TUNEL analysis, and quantification of caspase 8 (C), 6 h after 25 mg/kg ConA revealed strong attenuation of ConA hepatitis in NEMO\^hepa mice when NK1.1 mAb was administered 40 h before insult. (D and E) mRNA levels of IFN-y, CCL5, and IL-4 (D) and ELISA of IFN-y and TNF (E) on serum confirmed attenuation of ConA damage in NEMO\^hepa mice after NK1.1 mAb. (F–H) Adoptive transfer of TRAIL^-/- MNCs
Recent work showing that TRAIL−/− mice are protected from ConA-induced liver injury highlighted the important role of TRAIL in this model (Zheng et al., 2004). Thus, we examined if this cytokine may be an essential mediator of ConA liver damage in our NEMOΔhepa mice. We performed intrahepatic adoptive transfer of splenic mononuclear cells (MNCs) from TRAIL−/− or TRAIL+/+ mice before ConA administration in NK1.1−/−depleted mice. Liver damage was strongly attenuated in NEMOΔhepa mice receiving TRAIL−/− MNCs in contrast to TRAIL+/+ MNC transferred mice, where injury was restored (Fig. 5, F and G). Additionally, adoptive transfer of TRAIL−/− MNCs into NK1.1−/−depleted NEMOΔhepa mice restored both liver and systemic IFN-γ expression after ConA, whereas it remained low in NEMOΔhepa mice receiving TRAIL−/− MNCs (Fig. 5 H). The essential implication of NK cell–derived TRAIL in mediating ConA hepatitis in NEMOΔhepa mice was further confirmed by adoptive transfer of isolated NK1.1+ cells from TRAIL−/− mice, which preserved liver protection against ConA injury elicited by NK1.1 mAb (Fig. 5, F–H).

During ConA-mediated hepatitis, JNK activation is related to the degree of apoptosis and the severity of the cellular stress (Trautwein et al., 1998). Additionally, we showed the detrimental effects of the TRAIL-J NK cascade in NEMOΔhepa mice both in vivo and in vitro (Fig. 2 and S2). Accordingly, strong JNK activation was observed in NEMOΔhepa mice after ConA, whereas it was clearly blunted after NK1.1 mAb despite ConA administration (Fig. 5 I). JNK activation was restored after adoptive transfer of TRAIL−/− MNCs in NEMOΔhepa mice after ConA despite NK1.1 mAb treatment. On the contrary, transfer of both TRAIL+/+ MNCs and TRAIL−/− NK1.1+ cells maintained the resistance of NK1.1−/−depleted NEMOΔhepa mice to ConA-mediated JNK activation (Fig. 5 I).

Previous studies using a NK1.1 mAb described that NKT cells are an essential cell subset responsible for ConA-mediated liver injury as selective depletion of NK cells with an anti-asialo GM1 antibody had no impact on ConA hepatitis (Toyabe et al., 1997). However, our present data strongly support the hypothesis that NK cell–derived TRAIL plays a key role in the progression of ConA-induced liver damage in NEMOΔhepa mice. Accordingly, we observed that NK cell depletion with asialo-GM1 mAb significantly reduced ALT levels (2.17-fold; Fig. S4 A), a comparable effect to that observed with NK1.1 mAb (Fig. 5 A; 2.56-fold reduction). Accordingly, hematoxylin and eosin (H&E) and TUNEL assay revealed significant protection against ConA after NK cell depletion (Fig. S4, B and C), accompanied by reduced CCL5 in asialo-GM1–treated NEMOΔhepa mice. Interestingly, despite the clear protection elicited by NK cell depletion, we found high IL-4 mRNA expression in asialo-GM1 mAb–treated KOs (Fig. S4 D) suggesting remnant activation of NKT cells. Moreover, downregulation of serum IFN-γ levels supports the implication of this cytokine in the activation and production of TRAIL from NK cells in an autocrine fashion (Smyth et al., 2001; Takeda et al., 2001). This data strongly supports the essential role of TRAIL-producing NK cells in mediating the dramatic impact of ConA on NEMOΔhepa mice.

Our present study uncovers a new mechanism by which hepatocyte-specific NEMO deletion contributes to spontaneous liver inflammation and injury. We show that NEMO deletion sensitizes the liver to TRAIL–mediated apoptosis and this contributes to disease progression. We propose a dual mechanism consisting of up-regulation of DR5 on hepatocytes and the activation of TRAIL–producing NK cells to cause the detrimental effects of NEMO deletion in the liver. The first mechanism is supported by studies showing that steatosis and free fatty acids promote up-regulation of DR5 mRNA expression (Malhi et al., 2007). Additionally, the profuse bile acid accumulation found in livers of NEMOΔhepa mice (unpublished data) may further promote DR5 expression (Higuchi et al., 2004). In addition to increased DR5 expression, fatty liver disease also triggers NKT cell activation, leading to a proinflammatory cytokine response (Li et al., 2005), which we also observed in our NEMOΔhepa mice.

Additionally, it has been shown that NKT cells promote NK cell activation and TRAIL production through IFN-γ expression (Smyth et al., 2001). At present, the relevance of intestinal bacterial products transported into the liver through the blood stream and its role in NK and NKT cell activation is unclear in this model. However, this mechanism could also be relevant, as LPS induces macrophages to produce IL-12, triggering IFN-γ production by NKT cells in the absence of IL-4 (Dobashi et al., 1999; Guebre–Xabier et al., 2000). This scenario closely resembles the liver environment found in untreated NEMOΔhepa mice.

Our present work strengthens the essential role of hepatocyte NEMO/NF-kB to maintain liver homeostasis because absence of NEMO in these cells activates the innate immune system, thus promoting liver damage. The cascade of molecular events leading from steatohepatitis to fibrosis and tumor development observed in NEMOΔhepa mice reflects the pathogenesis of liver cirrhosis and HCC in humans. Further work in this model could yield novel therapeutic strategies targeting the NK cell/TRAIL axis to modulate chronic liver disease progression.

**MATERIALS AND METHODS**

**Generation of hepatocyte-specific conditional NEMO KO mice.** We generated mice carrying the loxP site–flanked (floxed [f]) NEMO gene (NEMOΔ) as described in detail in the supplemental figures. We generated NEMOΔhepa mice by crossing NEMOΔ mice with alfp-cre transgenic animals. For

and liver TRAIL−/− NK1.1+ cells after NK1.1 mAb protected while TRAIL+/+ MNC transfer restored ConA injury in NEMOΔhepa mice as shown by serum ALT (F), H&E staining (G), and ELISA (H) of IFN-γ serum levels. (I) ConA–mediated JNK activation was attenuated by NK1.1 mAb and restored by TRAIL−/− MNCs adoptive transfer. TRAIL−/− cells maintained JNK inactivated. JNK1 and GAPDH act as loading control. Bars, 50 μm. All data are representative of three independent experiments. n = 4. **, P < 0.01; ***, P < 0.001 [NEMOΔhepa vs. ConA/NEMOΔhepa]. $, P < 0.05; $#, P < 0.01; $##, P < 0.001 (ConA/NEMOΔhepa vs. NK1.1 mAb/ConA/NEMOΔhepa).
the experiments described, we used 8-wk-old male (Jo2 and TRAIL [provided by S. Bronk, Mayo Clinic College of Medicine, Rochester, MN]) and female (NK1.1 mAb and ConA) mice. Animals were treated according to the guidelines of the National Academy of Sciences (National Institutes of Health publication 86-23, revised 1985). Animal husbandry and procedures were approved by the authority for environment conservation and consumer protection of the state North Rhine–Westfalia (LANUV) and the University Hospital Aachen Animal Care Facility’s guidelines.

Models of liver injury. Jo2 (0.5 µg/g of body weight; BD) was injected i.p. and mice were sacrificed 3 h later. ConA (Sigma-Aldrich) was administered i.v. for either 6 h (15 mg/kg of body weight) or 24 h (25 mg/kg). Flagged TRAIL (Higuchi et al., 2002) was administered i.v. at a concentration of 25 mg/kg.

Analysis of gene and serum protein expression. RNA was isolated with PeqGold-RNA pure kit (Peqlab) from livers. Quantitative real-time PCR (iQ SYBR green reagent (Invitrogen)) in a 7300 Real-Time PCR system (Applied Biosystems). GAPDH was used to normalize gene expression, which is represented as times versus NEMO/NF-κB basal expression. Liver and serum TNF and serum IFN-γ levels were quantified by ELISA (R&D Systems and BD, respectively).

Statistical analysis. Data are expressed as mean ± standard deviation of the mean. Statistical significance was determined by two-way analysis of variance followed by a Student’s t test.

Online supplemental material. Fig. S1 shows the gene-targeting strategy for the generation of hepatocyte-specific NEMO KO mice. Fig. S2 demonstrates the efficacy of TRAIL on primary hepatocytes. Fig. S3 shows the survival curve after ConA treatment. Fig. S4 shows the effects of asialo-GM1 mAb administration during ConA hepatitis. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20082152/DC1.

We want to thank Steve Bronk for providing us with the TRAIL protein. We also want to thank Sara Dutton Sackett for editing the manuscript.

This work was supported by the SFB542, C19. The authors declare that they have no competing financial interests.

Submitted: 25 September 2008
Accepted: 30 June 2009

REFERENCES

Beraza N., T. Luedde, U. Assmus, T. Roskams, S. Vander Borght, and C. Trautwein. 2007. Hepatocyte-specific IKK gamma/NEMO expression determines the degree of liver injury. Gut 58:2504–2517.

Dobashi, H., S. Seki, Y. Haba, T. Ohkawa, S. Takeshita, H. Hirai, and I. Sekine. 1999. Activation of mouse liver natural killer cells and CD11k(+) T cells by bacterial superantigen-primed Kupffer cells. Hepatology 30:430–436.

Guebre-Xabier, M., S. Yang, H.Z. Lin, R. Schwenk, U. Krzych, and A.M. Diehl. 2000. Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: potential mechanism for sensitization to liver damage. Hepatology 31:633–640.

Hatazo, E., C.A. Bradam, A. Stark, Y. Immuro, J.J. Lennamers, and D.A. Brenner. 2000. The mitochondrial permeability transition augments Fas-induced apoptosis in mouse hepatocytes. J. Biol. Chem. 275:11814–11823.

Herr, I., D. Wilihelm, E. Meyer, I. Jeremias, P. Angel, and K.M. Debatin. 1999. JNK1/SAPK activity contributes to TRAIL-induced apoptosis. Cell Death Differ. 6:130–136.

Higuchi, H., S.F. Bronk, M. Tanai, A. Canbay, and G.J. Gores. 2002. Cholestasis increases tumor necrosis factor-related apoptosis-inducing h-gand (TRAIL)-R2/DR5 expression and sensitizes the liver to TRAIL-mediated cytotoxicity. J. Pharmacol. Exp. Ther. 303:461–467.

Higuchi, H., A. Gambhir, A. Canbay, S.F. Bronk, and G.J. Gores. 2004. Bile acids up-regulate death receptor 5/TRAIL-receptor 2 expression via a c-Jun N-terminal kinase-dependent pathway involving Sp1. J. Biol. Chem. 279:51–60.

Kellendonk, C., C. Opherk, A. Anlag, G. Schutz, and F. Trombe. 2000. Hepatocyte-specific expression of Cre recombinase. Genesis 26:151–153.

Kuhnel, F., L. Zender, Y. Paul, M.K. Tietze, C. Trautwein, M. Manns, and S. Kubicke. 2000. NF-κB mediates apoptosis through transcriptional activation of Fas (CD95) in adenoviral hepatitis. J. Biol. Chem. 275:6421–6427.

Li, Z., M.J. Soloski, and A.M. Diehl. 2005. Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease. Hepatology 42:880–885.

Lous, H., O. Le Moine, M.O. Peny, E. Quertinmont, D. Fokan, M. Goldman, and J. Deviere. 1997. Production and role of interleukin-10 in concanavalin A-induced hepatitis in mice. Hepatology 25:1382–1389.

Lu, B., L. Wang, D. Medan, D. Toledo, C. Huang, F. Chen, X. Shi, and Y. Rojanasakul. 2002. Regulation of Fas (CD95)-induced apoptosis by nuclear factor-kappaB and tumor necrosis factor-alpha in macrophages. Am. J. Physiol. Cell Physiol. 283:C381–C388.

Luedde, T., N. Beraza, V. Kotsikoris, G. Van Loo, A. Nenci, R. De Vos, T. Roskams, C. Trautwein, and M. Pasparakis. 2007. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepato-cellular carcinoma. Cancer Cell 11:119–132.

Luo, J.L., S. Macia, L.C. Hou, H. Yagita, and M. Karin. 2004. Inhibition of NF-κB in cancer cells converts inflammation-induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression. Cancer Cell 6:297–305.

Luo, J.L., H. Kamata, and M. Karin. 2005. IKK/NF-κB signaling: balancing life and death—a new approach to cancer therapy. J. Clin. Invest. 115:2625–2632.

JEM
Malhi, H., F.J. Barreyro, H. Isomoto, S.F. Brunk, and G.J. Gores. 2007. Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut. 56:1124–1131.

Morris, M.A., and K. Ley. 2004. Trafficking of natural killer cells. Curr. Mol. Med. 4:431–438.

Ochi, M., H. Ohdan, H. Mitsuta, T. Onoe, D. Tokita, H. Hara, K. Ishiyama, W. Zhou, Y. Tanaka, and T. Asahara. 2004. Liver NK cells expressing TRAIL are toxic against self hepatocytes in mice. Hepatology. 39:1321–1331.

Ogasawara, J., R. Watanabe-Fukunaga, M. Adachi, A. Matsuzawa, T. Kasugai, Y. Kitamura, N. Itoh, T. Suda, and S. Nagata. 1993. Lethal effect of the anti-Fas antibody in mice. Nature. 364:806–809.

Rodriguez, C.I., F. Buchholz, J. Galloway, R. Sequerra, J. Kasper, R. Ayala, A.F. Stewart, and S.M. Dymecki. 2000. High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP. Nat. Genet. 25:139–140.

Schutze, S., V. Tchikov, and W. Schneider-Brachert. 2008. Regulation of TNFR1 and CD95 signalling by receptor compartmentalization. Nat. Rev. Mol. Cell Biol. 9:655–662.

Smyth, M.J., E. Cretney, K. Takeda, R.H. Wiltrout, L.M. Sedger, N. Kayagaki, H. Yagita, and K. Okumura. 2001. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon-γ-dependent natural killer cell protection from tumor metastasis. J. Exp. Med. 193:661–670.

Takeda, K., Y. Hayakawa, L. Van Kaer, H. Matsuda, H. Yagita, and K. Okumura. 2000. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc. Natl. Acad. Sci. USA. 97:5498–5503.

Takeda, K., Y. Hayakawa, M.J. Smyth, N. Kayagaki, N. Yamauchi, S. Kakuta, Y. Iwakura, H. Yagita, and K. Okumura. 2001. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat. Med. 7:94–100.

Toyabe, S., S. Seki, T. Iiai, K. Takeda, K. Shirai, H. Watanabe, H. Hiraike, M. Uchiyama, and T. Abo. 1997. Requirement of IL-4 and liver NK1+ T cells for concanavalin A-induced hepatic injury in mice. J. Immunol. 159:1537–1542.

Trautwein, C., T. Rakemann, D.A. Brenner, K. Streetz, L. Licato, M.P. Manns, and G. Tien. 1998. Concanavalin A-induced liver cell damage: activation of intracellular pathways triggered by tumor necrosis factor in mice. Gastroenterology. 114:1035–1045.

Trinchieri, G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3:133–146.

Vivier, E., E. Tomasello, M. Baratin, T. Walzer, and S. Ugolini. 2008. Functions of natural killer cells. Nat. Immunol. 9:503–510.

Zheng, S.J., P. Wang, G. Shabany, and Y.H. Chen. 2004. Critical roles of TRAIL in hepatic cell death and hepatic inflammation. J. Clin. Invest. 113:88–64.

Zou, C., J. Ma, X. Wang, L. Guo, Z. Zhu, J. Stoops, A.E. Eaker, C.J. Johnson, S. Strom, G.K. Michalopoulos, et al. 2007. Lack of Fas antagonism by Met in human fatty liver disease. Nat. Med. 13:1078–1085.